17th Jul 2019 13:48
(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in Vancouver, Canada.
The antibiotics developer said its preclinical data showed that SMT-571 is highly potential against 262 clinical strains of gonorrhoeae. In addition, SMT-571 did not show cross-resistance with any antibiotic currently or previously used to treat gonorrhoea infections.
"The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease," said David Roblin, president of Research & Development of Summit.
He added: "As shown by the preclinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains."
Summit shares were trading 2.1% higher on Wednesday in London at 24.50 pence each.
Related Shares:
SUMM.L